Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 95075A107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Moll Peter 13G | 5.2% |
9/21/2026
Event 9/18/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
RA Capital Management, L.P.
13D/A
|
4.1% |
7/2/2026
Event 6/30/2026
|
||
| RA Capital Management, L.P. | 4.1% | |||
| Peter Kolchinsky | 4.1% | |||
| Rajeev Shah | 4.1% | |||
| RA Capital Healthcare Fund, L.P. | 3.8% | |||
|
MPM BioVentures 2014, L.P.
13D/A
|
3.8% |
5/12/2026
Event 5/8/2026
|
||
| MPM BioVentures 2014, L.P. | 1.6% | |||
| MPM BioVentures 2014 (B), L.P. | 0.1% | |||
| MPM Asset Management Investors BV2014 LLC | 0.1% | |||
| UBS Oncology Impact Fund L.P. | 1.3% | |||
| MPM BioVentures 2014 GP LLC | 1.7% | |||
| MPM BioVentures 2014 LLC | 1.8% | |||
| Oncology Impact Fund (Cayman) Management L.P. | 1.3% | |||
| MPM BioImpact LLC | 1.3% | |||
| Ansbert Gadicke | 3.8% | |||
| Luke Evnin | 2.4% | |||
| Todd Foley | 1.8% | |||
| MPM Asset Management LLC | 0.3% | |||
| MPM Oncology Innovations Fund LP | 0.4% | |||
| MPM Oncology Innovations Fund GP LLC | 0.4% | |||
|
Longwood Fund III, L.P.
13G/A
|
3.5% |
2/11/2026
Event 12/31/2025
|
||
| Longwood Fund III GP, LLC | 3.5% | |||
| Longwood Fund III, L.P. | 3.5% | |||
|
PFM Health Sciences, LP
13G/A
|
0.9% |
8/14/2025
Event 6/30/2025
|
||
| PFM Health Sciences, LP | 0.9% | |||
| PFM Health Sciences GP, LLC | 0.9% | |||
| Partner Asset Management, LLC | 0.9% | |||
| Brian D. Grossman | 0.9% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 53.4 k | $49.3 k |
| 2026 Q2 | 47 | 10.9 M | $3.91 M |
| 2026 Q1 | 48 | 14.0 M | $11.7 M |
| 2025 Q4 | 51 | 14.7 M | $9.34 M |
| 2025 Q3 | 64 | 21.1 M | $41.6 M |
| 2025 Q2 | 67 | 22.3 M | $24.3 M |
| 2025 Q1 | 73 | 27.4 M | $26.7 M |
| 2024 Q4 | 77 | 28.2 M | $41.7 M |
| 2024 Q3 | 73 | 32.2 M | $68.3 M |
| 2024 Q2 | 77 | 32.5 M | $79.4 M |
| 2024 Q1 | 68 | 32.4 M | $210 M |
| 2023 Q4 | 46 | 27.7 M | $107 M |
| 2023 Q3 | 36 | 23.9 M | $51.1 M |
| 2023 Q2 | 37 | 24.0 M | $73.3 M |
| 2023 Q1 | 39 | 24.0 M | $62.5 M |
| 2022 Q4 | 42 | 20.9 M | $42.9 M |
| 2022 Q3 | 45 | 21.0 M | $94.5 M |
| 2022 Q2 | 47 | 19.1 M | $78.0 M |
| 2022 Q1 | 50 | 19.0 M | $84.3 M |
| 2021 Q4 | 53 | 19.2 M | $228 M |
| 2021 Q3 | 43 | 19.0 M | $326 M |
| 2021 Q2 | 46 | 19.8 M | $344 M |